Grand Brilliance Group Holdings Limited (HKG:8372)
0.1400
-0.0010 (-0.71%)
Feb 6, 2026, 3:02 PM HKT
HKG:8372 Revenue
Grand Brilliance Group Holdings had revenue of 52.49M HKD in the half year ending September 30, 2025, with 27.08% growth. This brings the company's revenue in the last twelve months to 105.25M, up 27.91% year-over-year. In the fiscal year ending March 31, 2025, Grand Brilliance Group Holdings had annual revenue of 94.45M with 15.32% growth.
Revenue (ttm)
105.25M
Revenue Growth
+27.91%
P/S Ratio
1.06
Revenue / Employee
2.11M
Employees
50
Market Cap
112.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 94.45M | 12.55M | 15.32% |
| Mar 31, 2024 | 81.90M | 5.20M | 6.78% |
| Mar 31, 2023 | 76.70M | 4.72M | 6.56% |
| Mar 31, 2022 | 71.98M | 1.74M | 2.47% |
| Mar 31, 2021 | 70.24M | 3.01M | 4.48% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinopharm Group | 626.85B |
| Charmacy Pharmaceutical | 4.65B |
| Sipai Health Technology | 3.75B |
| ETHK Labs | 3.37B |
| Sinco Pharmaceuticals Holdings | 2.73B |
| ClouDr Group | 2.47B |
| 160 Health International | 698.59M |
| Ziyuanyuan Holdings Group | 575.61M |